BioCentury | Jan 6, 2021
Deals

Jan. 5 Quick Takes: Myriad restructuring; plus ViGeneron-Biogen, Rhythm, Sosei and more

...granted a second emergency use authorization to the MidaSpot COVID-19 Antibody Combo Detection Kit, from Nirmidas Biotech Inc....
...receptorPCSK1 – Proprotein convertase subtilisin/kexin type 1POMC – Proopiomelanocortin BC Staff HGH-CTP, Lagova, somatrogon (MOD-4023, PF-06836922) ViGeneron Gmbh Biogen Inc. Nirmidas Biotech Inc. Pfizer...
BioCentury | Mar 15, 2017
Distillery Techniques

Assays and screens

...Zika patients from the dengue patients with 89.7% sensitivity and 98.4% specificity. Next steps by Nirmidas Biotech Inc....
...Nirmidas Biotech Inc., Palo Alto, Calif. email: bo.zhang@nirmidas.com CONTACT: Hongjie Dai, Stanford University, Stanford, Calif. email: hdai@stanford.edu Hongjiang Li Nirmidas Biotech Inc. Stanford...
BioCentury | Oct 6, 2014
Emerging Company Profile

Nirmidas: Improving NIR-sightedness

...joint facility. Companies and Institutions Mentioned California Institute for Quantitative Biosciences (QB3), San Francisco, Calif. Nirmidas Biotech Inc....
BioCentury | Oct 6, 2014
Emerging Company Profile

Improving NIR-sightedness: Sidebar: Nirmidas Biotech Inc. Corporate Profile

Nirmidas Biotech Inc. San Francisco, Calif. Technology: Platform to amplify fluorescence of dye molecules Disease focus: Diagnostic Clinical status: Development Founded: 2013 by Meijie Tang and Hongjie Dai University collaborators: None Corporate partners: Undisclosed Number...
BioCentury | Sep 1, 2014
Financial News

Nirmidas Biotech completes venture financing

Nirmidas Biotech Inc. , San Francisco, Calif. Business: Diagnostic Date completed: 2014-08-18 Type: Venture financing Raised: $2 million Investors: Stanford StartX Fund; angel investor; and an undisclosed investor WIR Staff Diagnostic...
BioCentury | Aug 19, 2014
Financial News

Nirmidas raises $2 million in seed round

Nirmidas Biotech Inc. (San Francisco, Calif.) raised $2 million in a seed round from an undisclosed VC firm, a life science angel investor and Stanford StartX. The funds will be used to commercialize Nirmidas' pGOLD...
Items per page:
1 - 6 of 6
BioCentury | Jan 6, 2021
Deals

Jan. 5 Quick Takes: Myriad restructuring; plus ViGeneron-Biogen, Rhythm, Sosei and more

...granted a second emergency use authorization to the MidaSpot COVID-19 Antibody Combo Detection Kit, from Nirmidas Biotech Inc....
...receptorPCSK1 – Proprotein convertase subtilisin/kexin type 1POMC – Proopiomelanocortin BC Staff HGH-CTP, Lagova, somatrogon (MOD-4023, PF-06836922) ViGeneron Gmbh Biogen Inc. Nirmidas Biotech Inc. Pfizer...
BioCentury | Mar 15, 2017
Distillery Techniques

Assays and screens

...Zika patients from the dengue patients with 89.7% sensitivity and 98.4% specificity. Next steps by Nirmidas Biotech Inc....
...Nirmidas Biotech Inc., Palo Alto, Calif. email: bo.zhang@nirmidas.com CONTACT: Hongjie Dai, Stanford University, Stanford, Calif. email: hdai@stanford.edu Hongjiang Li Nirmidas Biotech Inc. Stanford...
BioCentury | Oct 6, 2014
Emerging Company Profile

Nirmidas: Improving NIR-sightedness

...joint facility. Companies and Institutions Mentioned California Institute for Quantitative Biosciences (QB3), San Francisco, Calif. Nirmidas Biotech Inc....
BioCentury | Oct 6, 2014
Emerging Company Profile

Improving NIR-sightedness: Sidebar: Nirmidas Biotech Inc. Corporate Profile

Nirmidas Biotech Inc. San Francisco, Calif. Technology: Platform to amplify fluorescence of dye molecules Disease focus: Diagnostic Clinical status: Development Founded: 2013 by Meijie Tang and Hongjie Dai University collaborators: None Corporate partners: Undisclosed Number...
BioCentury | Sep 1, 2014
Financial News

Nirmidas Biotech completes venture financing

Nirmidas Biotech Inc. , San Francisco, Calif. Business: Diagnostic Date completed: 2014-08-18 Type: Venture financing Raised: $2 million Investors: Stanford StartX Fund; angel investor; and an undisclosed investor WIR Staff Diagnostic...
BioCentury | Aug 19, 2014
Financial News

Nirmidas raises $2 million in seed round

Nirmidas Biotech Inc. (San Francisco, Calif.) raised $2 million in a seed round from an undisclosed VC firm, a life science angel investor and Stanford StartX. The funds will be used to commercialize Nirmidas' pGOLD...
Items per page:
1 - 6 of 6